Lupin Limited has informed the Exchange regarding a press release dated Jun 04, 2026, titled " Lupin Receives Approval from U.S. FDA for Ranluspec (ranibizumab) Injection".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has received approval from the U.S. FDA for Ranluspec, its ranibizumab injection product, marketed for treating serious eye conditions such as wet age-related macular degeneration. Ranibizumab is a key biologic drug (biosimilar referencing Lucentis) used in ophthalmology and commands a large market in the United States. This approval allows Lupin to manufacture and commercialize the product in the lucrative U.S. market, adding a high-value product to its specialty portfolio. The approval strengthens Lupin's specialty and complex generics pipeline alongside its existing biosimilar strategy.
This is a positive development for Lupin shareholders as it opens access to a high-margin specialty biologic market in the U.S., potentially boosting future revenues from the complex injectables segment. U.S. specialty/biosimilar approvals are typically seen positively by the market but near-term stock impact depends on launch timelines and competition.